Regenxbio Inc stock is traded at $8.11, with a volume of 259,344. It is down -4.31% in the last 24 hours and up +4.31% over the past month. Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Previous Close:
$8.47
Open:
$8.23
24h Volume:
259,344
Relative Volume:
0.20
Market Cap:
$535.92M
Revenue:
$170.44M
Net Income/Loss:
-$193.88M
P/E Ratio:
-
EPS:
-$3.75
Net Cash Flow:
-$126.38M
1W Performance:
+9.82%
1M Performance:
+4.31%
6M Performance:
-20.85%
1Y Performance:
-30.13%
1-Day Range:
$7.94$8.33
1-Week Range:
$7.28$8.88
52-Week Range:
$5.46$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio IncSector
HealthcareIndustry
BiotechnologyPhone
240-552-8181Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS